Educational Risk Mininimisation Materials to help reduce the risk associated with use of natalizumab (Tysabri) for the treatment of multiple sclerosis

A guidance document for physicians provides additional risk mitigation measures, focusing on progressive multifocal leukoencephalopathy, which is the most important adverse reaction affecting patients treated with natalizumab.

SPS commentary:

The physician’s guidance is supported by a Treatment Initiation Form, Treatment Continuation Form, and Treatment Discontinuation Form. A patient alert card containing important safety information that patients need to be aware of before, during and after stopping treatment with natalizumab is also available.

Biogen

Resource links:

Patient alert card

Treatment initiation form

Treatment continuation form

Treatment discontinuation form

Physician information and management guidelines